Management of breast cancer patients with BRCA gene mutations in Jordan: perspectives and challenges

References

• Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2021 May [cited 2022 Aug 22];71(3); 209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Ministry Of Health. Jordan Cancer Registry Cancer Incidence In Jordan 2018 [Internet]. 2018 [cited 2023 May 24]. Available from: https://moh.gov.jo/ebv4.0/root_storage/ar/eb_list_page/التقرير_السنوي_لاصابات_السرطان_المسجلة_في_الاردن_لعام_2018.pdf
   Google Scholar
• Abdel-Razeq H, Mansour A, Jaddan D. Breast cancer care in Jordan. JCO Glob Oncol. 2020 [cited 2022 Sep 20];6:260–268. PMC7051801. doi: 10.1200/JGO.19.00279.
   PubMedGoogle Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014 May 14;106(5). doi: 10.1093/jnci/dju055
   PubMedGoogle Scholar
• Tomasello G, Gambini D, Petrelli F, et al. Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis. ESMO Open. 2022 Aug 1;7(4):100531. doi: 10.1016/j.esmoop.2022.100531
   PubMed Web of Science ®Google Scholar
• Armstrong N, Ryder S, Forbes C, et al. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019 Jul 11 [cited 2022 Sep 21];11:543–561. doi: 10.2147/CLEP.S206949
   PubMed Web of Science ®Google Scholar
• Toland AE, Forman A, Couch FJ, et al. Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. NPJ Genom Med. 2018 Feb 15 [cited 2022 Oct 30];3(1):1–8. doi: 10.1038/s41525-018-0046-7
   PubMedGoogle Scholar
• Sughayer MA, Al-Khawaja MM, Massarweh S, et al. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathol Oncol Res [Internet]. 2006 Jun;12(2):83–86. doi: 10.1007/BF02893449
   PubMed Web of Science ®Google Scholar
• Fasching PA, Hu C, Hart S, et al. Germline BRCA1and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: data from the German PRAEGNANT registry. 2019 May 26;37(15_suppl):1048. doi: 10.1200/JCO20193715_suppl1048
   Google Scholar
• Zhu Y, Wu J, Zhang C, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016 [cited 2022 Sep 21];7(43):70113–70127. doi: 10.18632/oncotarget.12158
   PubMedGoogle Scholar
• Engel C, Rhiem K, Hahnen E, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. 2018 Mar 7 [cited 2022 Sep 21];18(1):1–6. doi: 10.1186/s12885-018-4029-y
   PubMedGoogle Scholar
• Geredeli C, Yasar N, Sakin A. Germline mutations in BRCA1 and BRCA2 in breast cancer patients with high genetic risk in Turkish population. Int J Breast Cancer. 2019 [cited 2022 Sep 21];2019:1–7. PMC6332947. doi: 10.1155/2019/9645147
   Web of Science ®Google Scholar
• Abulkhair O, Al BM, Makram O, et al. Prevalence of BRCA1 and BRCA2 mutations among high-risk Saudi patients with breast cancer. J Glob Oncol. 2018 Mar 1;2018(4). doi: 10.1200/JGO.18.00066
   Google Scholar
• Manchanda R, Sun L, Brentnall A, et al. A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol. 2019 Dec 1 [cited 2022 Sep 21];5(12):1718. PMC6777250. doi: 10.1001/jamaoncol.2019.3323
   PubMed Web of Science ®Google Scholar
• Abdel-Razeq H, Abujamous L, Abunasser M, et al. Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan. Sci Rep. 2021 Dec 1 [cited 2022 Sep 20];11(1). doi: 10.1038/s41598-021-94403-1
   Web of Science ®Google Scholar
• Abu-Helalah M, Azab B, Mubaidin R, et al. BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan. Sci Rep. 2020 Dec 1 [cited 2022 Sep 20];10(1). doi: 10.1038/s41598-020-74250-2
   PubMedGoogle Scholar
• Abdel-Razeq H, Tamimi F, Abujamous L, et al. Rates of variants of uncertain significance among patients with breast cancer undergoing genetic testing: regional perspectives. Front Oncol PMC8989924. 2022 Mar 25 [cited 2022 Sep 20]; 12:1. doi: 10.3389/fonc.2022.673094
   Web of Science ®Google Scholar
• NCCN. NCCN clinical practice guidelines in Oncology (NCCN guidelines ®) breast cancer version 4.2023 [Internet]. 2023 [cited 2023 May 24]. Available from: https://www.nccn.
   Google Scholar
• Dwyer M NCCN clinical practice guidelines in Oncology (NCCN guidelines ®) genetic/familial high-risk assessment: breast, ovarian, and pancreatic. 2023 [cited 2022 Sep 21]. Available from: https://www.nccn.org/home/member-
   Google Scholar
• Saadeh S, Abdel-Razeq H. Breast cancer in the Arab world. Cancer Arab World. 2022 [cited 2022 Sep 20];353–62. doi: 10.1007/978-981-16-7945-2_22
   Google Scholar
• Abdulrashid K, Alhussaini N, Ahmed W, et al. Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis. BMC Cancer. 2019 Mar 21 [cited 2022 Sep 20];19(1):1–12. doi: 10.1186/s12885-019-5463-1
   PubMedGoogle Scholar
• Alhuqail AJ, Alzahrani A, Almubarak H, et al. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in Arab breast and ovarian cancer patients. Breast Cancer Res Treat. 2018 Jan 2 [cited 2022 Sep 20];168(3):695–702. doi: 10.1007/s10549-017-4635-4
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J, Brezden-Masley C, Cazzaniga M, et al. Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study. Breast Cancer Res. 2020 Dec 1 [cited 2022 Sep 21];22(1):1–11. Available from. doi: 10.1186/s13058-020-01349-9
   Web of Science ®Google Scholar
• Manahan ER, Kuerer HM, Sebastian M, et al. Consensus guidelines on genetic` testing for hereditary breast cancer from the American society of breast surgeons. Ann Surg Oncol. 2019 Oct 1 [cited 2022 Oct 30];26(10):3025–3031. doi: 10.1245/s10434-019-07549-8
   PubMed Web of Science ®Google Scholar
• Culver JO, Freiberg Y, Ricker C, et al. Integration of universal germline genetic testing for all New breast cancer patients. Ann Surg Oncol Available from. 2022 Sep 26;30(2):1017–1025. doi: 10.1245/s10434-022-12595-w
   PubMed Web of Science ®Google Scholar
• De Silva DL, Stafford L, Skandarajah AR, et al. Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care. Med J Aust. 2023 May 1 [cited 2023 Aug 13];218(8):368–373. doi: 10.5694/mja2.51906
   PubMed Web of Science ®Google Scholar
• Muendlein A, Rohde BH, Gasser K, et al. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol. 2015 Nov 1 [cited 2022 Sep 21];141(11):2005–2012. doi: 10.1007/s00432-015-1986-2
   PubMed Web of Science ®Google Scholar
• Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019 Feb 2 [cited 2022 Sep 21];37(6):453. PMC6380523. doi: 10.1200/JCO.18.01631
   PubMed Web of Science ®Google Scholar
• Andoni T, Wiggins J, Robinson R, et al. Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria. Sci Rep. 2022 Feb 21 [cited 2022 Sep 21];12(1):1–14. doi: 10.1038/s41598-022-06376-4
   PubMed Web of Science ®Google Scholar
• Jones JC, Golafshar MA, Coston TW, et al. Universal genetic testing vs. Guideline-directed testing for hereditary cancer syndromes among traditionally underrepresented patients in a community Oncology program. Cureus. 2023 Apr 11 [cited 2023 Aug 13];15(4). doi: 10.7759/cureus.37428
   Web of Science ®Google Scholar
• Elalaoui SC, Laarabi FZ, Afif L, et al. Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA region. Breast Cancer Res Treat. 2022 Jul 1 [cited 2022 Sep 20];194(1):187–198. doi: 10.1007/s10549-022-06622-3
   PubMed Web of Science ®Google Scholar
• AbdelHamid SG, Zekri ARN, AbdelAziz HM, et al. BRCA1 and BRCA2 truncating mutations and variants of unknown significance in Egyptian female breast cancer patients. Clin Chim Acta. 2021 Jan 1;512:66–73. doi: 10.1016/j.cca.2020.11.023
   PubMed Web of Science ®Google Scholar
• Kawaji H, Kubo M, Yamashita N, et al. Comprehensive molecular profiling broadens treatment options for breast cancer patients. Cancer Med. 2021 Jan 1 [cited 2022 Sep 21];10(2):529–539. doi: 10.1002/cam4.3619
   PubMed Web of Science ®Google Scholar
• Meshkani Z, Aboutorabi A, Moradi N, et al. Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. Hered Cancer Clin Pract. 2021 Dec 1 [cited 2022 Sep 21];19(1). doi: 10.1186/s13053-021-00191-0
   PubMed Web of Science ®Google Scholar
• Manchanda R, Sun L, Patel S, et al. Economic evaluation of population-based BRCA1/BRCA2 mutation testing across multiple countries and health systems. Cancers (Basel). 2020 Jul 1 [cited 2022 Sep 21];12(7):1–38. doi: 10.3390/cancers12071929
   Web of Science ®Google Scholar
• Mousa R, Hammad E, Melhem J, et al. Direct medical costs of breast cancer in Jordan: cost drivers and predictors. Expert Rev Pharmacoecon Outcomes Res. 2021 [cited 2022 Sep 21];21(4):647–654. doi: 10.1080/14737167.2021.1859372
   PubMed Web of Science ®Google Scholar
• Carbonara N, La Forgia D, Pellegrino R, et al. A cost decision model supporting treatment strategy selection in BRCA1/2 mutation carriers in breast cancer. J Pers Med. 2021 Sep 1 [cited 2022 Sep 21];11(9): 847. PMC8470684. doi: 10.3390/jpm11090847
   PubMed Web of Science ®Google Scholar
• Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018 Apr 5 [cited 2022 Sep 21];4(4). doi: 10.1002/14651858.CD002748.pub4
   PubMedGoogle Scholar
• Choi YH, Terry MB, Daly MB, et al. Association of risk-reducing salpingo-oophorectomy with breast cancer risk in women with BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2021 Apr 1 [cited 2022 Sep 21];7(4):585–592. Available from: https://pubmed.ncbi.nlm.nih.gov/33630024/.
   PubMed Web of Science ®Google Scholar
• Eleje GU, Eke AC, Ezebialu IU, et al. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018 Aug 24 [cited 2022 Sep 21];8(8). doi: 10.1002/14651858.CD012464.pub2
   PubMedGoogle Scholar
• Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016 Aug 1 [cited 2022 Sep 21];22(15):3971–3981. doi: 10.1158/1078-0432.CCR-15-1465
   PubMed Web of Science ®Google Scholar
• Wang C, Lin Y, Zhu H, et al. Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis. Breast Cancer. 2022 Mar 1 [cited 2022 Sep 21];29(2):314–323. doi: 10.1007/s12282-021-01312-2
   PubMed Web of Science ®Google Scholar
• Co M, Liu T, Leung J, et al. Breast conserving surgery for BRCA mutation carriers—A systematic review. Clin Breast Cancer. 2020 Jun 1 [cited 2022 Oct 30];20(3):e244–50. doi: 10.1016/j.clbc.2019.07.014
   PubMed Web of Science ®Google Scholar
• Davey MG, Davey CM, Ryan J, et al. Combined breast conservation therapy versus mastectomy for BRCA mutation carriers – a systematic review and meta-analysis. Breast. 2021 Apr 1 [cited 2022 Oct 30];56:26–34. doi: 10.1016/j.breast.2021.02.001
   PubMed Web of Science ®Google Scholar
• Rashmi Kumar N, Berardi R, Abraham J, et al. NCCN guidelines version 4.2022 breast cancer. 2022 [cited 2022 Sep 21]. Available from: https://www.nccn1.
   Google Scholar
• DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol. 2019 [cited 2022 Sep 21];37(19):1629–1637. doi: 10.1200/JCO.18.01779
   PubMed Web of Science ®Google Scholar
• Mocellin S, Goodwin A, Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2019 Apr 29 [cited 2022 Sep 21];4(4). doi: 10.1002/14651858.CD012191.pub2
   PubMedGoogle Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10 [cited 2022 Oct 30];377(6):523–533. doi: 10.1056/NEJMoa1706450
   PubMed Web of Science ®Google Scholar
• Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2019 Apr 1 [cited 2022 Oct 30];30(4):558–566. doi: 10.1093/annonc/mdz012
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23 [cited 2022 Oct 30];379(8):753–763. doi: 10.1056/NEJMoa1802905
   PubMed Web of Science ®Google Scholar
• Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov 1 [cited 2022 Oct 30];31(11):1526–1535. doi: 10.1016/j.annonc.2020.08.2098
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Yuan L, et al. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis. Aging. 2020 Nov 30 [cited 2022 Oct 30];13(1):450–459. doi: 10.18632/aging.202152
   PubMedGoogle Scholar
• Han HS, Arun BK, Kaufman B, et al. Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial. Ann Oncol. 2022 Mar 1 [cited 2022 Oct 30];33(3):299–309. doi: 10.1016/j.annonc.2021.11.018
   PubMed Web of Science ®Google Scholar
• Diéras V, Han HS, Kaufman B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Oct 1 [cited 2022 Oct 30];21(10):1269–1282. doi: 10.1016/S1470-2045(20)30447-2
   PubMed Web of Science ®Google Scholar
• Edaily S, Abdel-Razeq H. Management strategies of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants. Onco Targets Ther. 2022 [cited 2022 Oct 30];15:815–826. doi: 10.2147/OTT.S369844
   PubMed Web of Science ®Google Scholar
• Taylor AM, Chan DLH, Tio M, et al. PARP (poly ADP-Ribose polymerase) inhibitors for locally advanced or metastatic breast cancer. Cochrane Database Syst Rev. 2021 Apr 22 [cited 2022 Sep 21];4(4). doi: 10.1002/14651858.CD011395.pub2
   PubMedGoogle Scholar
• Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Oct [cited 2022 Nov 27];40. http://www.annalsofoncology.org/article/S0923753422041655/fulltext
   Google Scholar
• Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021 Jun 24 [cited 2022 Nov 27];384(25):2394–2405. doi: 10.1056/NEJMoa2105215
   PubMed Web of Science ®Google Scholar
• Jacobs C, Patch C, Michie S. Communication about genetic testing with breast and ovarian cancer patients: a scoping review. Eur J Hum Genet. 2019 Apr 1 [cited 2022 Sep 21];27(4): 511. PMC6460583. doi: 10.1038/s41431-018-0310-4
   PubMed Web of Science ®Google Scholar
• Kurian AW, Griffith KA, Hamilton AS, et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017 Feb 7 [cited 2022 Sep 21];317(5):531–534. doi: 10.1001/jama.2016.16918
   PubMed Web of Science ®Google Scholar
• Scott N, O’Sullivan J, Asgeirsson K, et al. Changing practice: moving to a specialist nurse-led service for BRCA gene testing. Br J Nurs. 2020 May 28 [cited 2022 Sep 21];29(10):S6–13. doi: 10.12968/bjon.2020.29.10.S6
   PubMedGoogle Scholar
• van der Giessen J, Fransen MP, Spreeuwenberg P, et al. Communication about breast cancer genetic counseling with patients with limited health literacy or a migrant background: evaluation of a training program for healthcare professionals. J Community Genet. 2021 Jan 1 [cited 2022 Sep 21];12(1): 91. PMC7846648. doi: 10.1007/s12687-020-00497-x
   PubMed Web of Science ®Google Scholar
• Zakas AL, Leifeste C, Dudley B, et al. The impact of genetic counseling on patient engagement in a specialty cancer clinic. J Genet Couns. 2019 Oct 1 [cited 2022 Sep 21];28(5):974–981. doi: 10.1002/jgc4.1149.
   PubMed Web of Science ®Google Scholar
• Nelson HD, Pappas M, Cantor A, et al. Risk assessment, genetic counseling, and genetic testing for BRCA-Related cancer in women: updated evidence report and systematic review for the US Preventive Services task force. JAMA. 2019 Aug 20 [cited 2022 Sep 21];322(7):666–685. doi: 10.1001/jama.2019.8430
   PubMed Web of Science ®Google Scholar